BioCorRx. has filed a patent for a method using Compound 1 to treat various diseases and disorders, including pain, depression, schizophrenia, and substance use disorder with fewer withdrawal symptoms than standard opioid addiction treatments. GlobalData’s report on BioCorRx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCorRx, Nanoparticle drug conjugates was a key innovation area identified from patents. BioCorRx's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
A patent application (Publication Number: US20240009178A1) discloses a method for treating various diseases and disorders by administering a compound represented by a specific formula to human patients. The method includes treating conditions such as pain, depression, schizophrenia, obesity, weight gain, and substance use disorders without the use of opioids. In the case of substance use disorders, the compound induces fewer withdrawal symptoms compared to standard opioid addiction treatments like buprenorphine, methadone, naloxone, or naltrexone. The compound can be administered in varying doses ranging from 0.01 mg to 1000 mg daily, with administration frequencies of once, twice, three times, or four times a day.
The patent application outlines a method that offers a novel approach to treating a range of diseases and disorders by administering a specific compound to patients in need. By targeting conditions such as pain, depression, schizophrenia, obesity, weight gain, and substance use disorders without the use of opioids, the method presents a potentially groundbreaking alternative to traditional treatments. Additionally, the compound's ability to reduce withdrawal symptoms in substance use disorder cases compared to standard opioid addiction treatments could have significant implications for improving patient outcomes. The flexibility in dosing and administration frequency further enhances the method's adaptability to individual patient needs, potentially offering a more personalized and effective treatment approach.
To know more about GlobalData’s detailed insights on BioCorRx, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
